<DOC>
	<DOCNO>NCT00002998</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness gemcitabine cisplatin treat patient metastatic breast cancer respond systemic therapy .</brief_summary>
	<brief_title>Gemcitabine Cisplatin Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response rate gemcitabine cisplatin treatment metastatic breast cancer patient fail one two systemic regimen . II . Determine time progression survival patient . III . Define toxicity two-drug combination patient . OUTLINE : This nonrandomized study . Patients receive gemcitabine IV 30 minute cisplatin IV 1 hour day 1 , 8 , 15 every 28 day . Patients complete response may receive additional 2 course attainment complete response status . Treatment continue absence disease progression unacceptable toxicity maximum 8 course . Patients follow every 3 month 2 year 3 year treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic cytologic confirmation metastatic breast cancer two exception : New enlarge pulmonary nodule demonstrable two chest radiograph take least one month apart OR Multiple characteristic lytic bone metastasis liver metastases Measurable indicator lesion Measurable metastatic disease must bidimensionally measurable except case hepatomegaly may unidimensionally measurable Patients receive bisphosphonates must measurable disease bone No CNS metastases unless control prior surgery and/or radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : WBC least 3500/mm3 absolute neutrophil count least 2000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 0.3 mg/dL upper limit normal limit ( ULN ) AST great 3 time ULN Renal : Creatinine great 0.3 mg/dL ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : Physicianestimated oral caloric intake least 1200 calorie per day No uncontrolled infection chronic debilitate disease Not pregnant nursing Women childbearing potential must use adequate contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Must previously receive 1 2 chemotherapy regimen At least 1 prior regimen administer metastatic disease At least 1 prior regimen contain anthracycline paclitaxel At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy No prior strontium 89 radiotherapy Prior radiotherapy must less 25 % bone marrow Surgery : At least 4 week since major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>